VYNT · Vyant Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $666.0K | $1.15M | $5.75M | $7.30M | $29.12M | $29.12M |
| Cost of Revenue | - | - | $3.35M | $3.70M | $18.72M | $18.07M |
| Gross Profit | - | - | $2.40M | $3.60M | $8.75M | $11.05M |
| R&D | $6.77M | $3.23M | - | $0 | $2.49M | $4.79M |
| SG&A | - | - | $6.59M | $5.17M | $19.18M | $19.89M |
| Total Operating Expenses | $16.58M | $16.85M | $10.58M | $9.31M | $30.72M | $29.67M |
| D&A | $522.0K | $572.0K | $166.0K | $159.0K | $1.60M | $1.80M |
| Operating Income | ($15.91M) | ($15.71M) | ($8.18M) | ($5.70M) | ($21.98M) | ($18.62M) |
| Interest Expense | - | - | $272.0K | $1.44M | $2.12M | $2.13M |
| Income Tax | - | - | $0 | ($512.0K) | $0 | ($2.08M) |
| Net Income | ($22.69M) | ($40.86M) | ($8.00M) | ($6.71M) | ($20.37M) | ($20.88M) |
| EPS - Basic | ($3.87) | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.04M | $20.61M | $2.44M | $3.88M | $161.0K | $9.54M |
| Accounts Receivable | $323.0K | $434.0K | $779.0K | $696.0K | $7.04M | $10.96M |
| Inventory | $53.0K | $475.0K | - | - | $144.0K | $144.0K |
| Accounts Payable | $655.0K | $740.0K | - | - | - | - |
| Current Assets | $11.51M | $23.21M | $4.11M | $7.18M | $9.35M | $23.21M |
| Total Assets | $15.21M | $37.64M | $8.35M | $14.90M | $35.41M | $52.22M |
| Current Liabilities | $3.67M | $5.43M | $4.26M | $6.97M | $27.29M | $19.64M |
| Long-term Debt | $57.0K | $57.0K | - | - | - | - |
| Total Liabilities | $5.30M | $6.35M | $4.37M | $7.52M | $28.60M | $25.46M |
| Stockholders' Equity | $9.91M | $31.29M | $3.98M | $7.38M | $6.80M | $26.77M |
| Retained Earnings | ($101.50M) | ($78.81M) | ($172.43M) | ($164.42M) | ($157.72M) | ($134.83M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($13.68M) | ($16.99M) | ($5.37M) | ($8.66M) | ($12.55M) | ($13.56M) |
| Investing Cash Flow | $3.26M | $29.62M | $1.01M | $9.09M | $1.08M | ($2.75M) |
| Financing Cash Flow | ($149.0K) | $7.19M | $2.64M | $3.31M | $2.15M | $16.34M |
| CapEx | $617.0K | $535.0K | $39.0K | $28.0K | $649.0K | $1.28M |
| Free Cash Flow | ($14.30M) | ($17.53M) | ($5.41M) | ($8.69M) | ($13.20M) | ($14.85M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | 41.7% | 49.3% | 30.0% | 37.9% |
| Operating margin | -2389.2% | -1368.1% | -142.3% | -78.1% | -75.5% | -63.9% |
| EBITDA margin | -2310.8% | -1318.3% | -139.4% | -75.9% | -70.0% | -57.8% |
| Net margin | -3406.9% | -3559.1% | -139.1% | -91.8% | -70.0% | -71.7% |
| Free cash flow margin | -2146.8% | -1526.8% | -94.1% | -118.9% | -45.3% | -51.0% |
| FCF / Net income | 0.63 | 0.43 | 0.68 | 1.30 | 0.65 | 0.71 |
| R&D / Revenue | 1016.8% | 281.5% | - | 0.0% | 8.5% | 16.4% |
| SG&A / Revenue | - | - | 114.7% | 70.8% | 65.9% | 68.3% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -149.2% | -108.6% | -95.8% | -45.0% | -57.5% | -40.0% |
| Return on equity | -229.0% | -130.6% | -201.0% | -90.8% | -299.5% | -78.0% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 3.14 | 4.27 | 0.96 | 1.03 | 0.34 | 1.18 |
| Quick ratio | 3.13 | 4.19 | 0.96 | 1.03 | 0.34 | 1.17 |
| Cash ratio | 2.74 | 3.79 | 0.57 | 0.56 | 0.01 | 0.49 |
| Leverage | ||||||
| Debt / Equity | 0.01 | 0.00 | - | - | - | - |
| Debt / Assets | 0.00 | 0.00 | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | -30.1x | -4.0x | -10.4x | -8.8x |
| Equity multiplier | 1.53 | 1.20 | 2.10 | 2.02 | 5.21 | 1.95 |
| Liabilities / Assets | 0.35 | 0.17 | 0.52 | 0.50 | 0.81 | 0.49 |
| Efficiency | ||||||
| Asset turnover | 0.04 | 0.03 | 0.69 | 0.49 | 0.82 | 0.56 |
| Inventory turnover | - | - | - | - | 130.03 | 125.49 |
| Days sales outstanding | 177d | 138d | 49d | 35d | 88d | 137d |
| Days inventory outstanding | - | - | - | - | 3d | 3d |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -42.0% | -80.0% | -21.3% | -74.9% | 0.0% | 7.7% |
| Revenue CAGR (3y) | -55.0% | -66.0% | -41.8% | -35.4% | 17.3% | 41.9% |
| Revenue CAGR (5y) | -53.0% | -46.8% | -20.4% | -6.5% | 46.6% | - |
| Gross profit growth (YoY) | - | - | -33.5% | -58.8% | -20.9% | 11.1% |
| Operating income growth (YoY) | -1.3% | -91.9% | -43.5% | 74.1% | -18.0% | -11.3% |
| Net income growth (YoY) | 44.5% | -410.7% | -19.3% | 67.1% | 2.4% | -32.1% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 18.4% | -224.0% | 37.7% | 34.2% | 11.1% | 19.0% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -68.3% | 686.2% | -46.1% | 8.6% | -74.6% | 4.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$1.15M totalService$665.0K · 57.9%
Product$483.0K · 42.1%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-7.71
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing Vyant Bio against the 5 most active filers in the same SIC group.